Ellie Mertens reviews Canada’s most notable cases last year, including the highly anticipated ruling on the promise doctrine, the largest award for patent infringement in Canadian history, and trade mark disputes

The rejection of the promise doctrine has brought Canada into line with other countries and been welcomed by pharmaceutical companies. It also raises questions such as how courts will determine the “subject matter of the invention” and how the enhanced disclosure requirement will be resolved